Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Immuno-Oncology in Pancreatic Ductal Adenocarcinoma: Biological Rationale, Clinical Progress, and Future Directions

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies, characterised by rising incidence, poor long-term survival, and profound resistance to systemic therapy. Its poor prognosis reflects late diagnosis, early metastatic spread, and a uniquely desmoplastic, immunosuppressive tumour microe...

A. Lefas, H. Lote, I. Chau · 0 citations
Review Open access Aug 2026

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648.

BACKGROUND Nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit compared with chemotherapy for patients with previously untreated advanced esophageal squamous cell carcinoma (ESCC). We report OS and additional analyses at a minimum follow-up of 5 years....

K. Kato, J. Ajani, Y. Doki et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.